Minurin (Desmopressin Acetate)

Desmopressin acetate, the active ingredient in Minurin, is a vasopressin analog presented as a nasal spray for nasal use. It treats central diabetes insipidus, nocturnal enuresis, and serves as an adjunct in hemophilia A therapy. GNH USA supplies Minurin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Desmopressin acetate is used to manage conditions related to antidiuretic hormone deficiency or bleeding disorders.

Central diabetes insipidus: reduces excessive urine output by increasing renal water reabsorption. Nocturnal enuresis: decreases nighttime bedwetting by concentrating urine. Hemophilia A (adjunct therapy): raises plasma factor VIII and von Willebrand factor levels to aid haemostatic control.

Desmopressin nasal spray may cause a range of adverse reactions.

Common Side Effects: - Nasal irritation or congestion. - Headache. - Mild hyponatraemia. - Thirst or dry mouth. - Nausea. - Transient facial flushing.

Serious or Rare Side Effects: - Severe hyponatraemia leading to seizures or coma. - Water intoxication with cerebral oedema. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Hypertensive crisis (rare). - Cardiac arrhythmias in susceptible patients. - Persistent nasal bleeding.

Before prescribing Minurin, clinicians should consider several safety measures. - Renal function: assess and monitor in patients with impaired renal clearance. - Fluid intake: advise restriction of excessive fluids to minimise hyponatraemia risk. - Electrolytes: check serum sodium before initiation and periodically during therapy. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Concomitant antidiuretic agents: avoid combined use to prevent severe water retention. - Store below 25°C: keep in the original container, protect from moisture and light.

Desmopressin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Other vasopressin analogues (e.g., vasopressin): additive antidiuretic effect can cause profound hyponatraemia. - Strong CYP2C9 inhibitors (e.g., fluconazole): may increase desmopressin plasma levels.

Moderate Interactions (Monitor Closely): - NSAIDs: can potentiate renal water reabsorption and raise hyponatraemia risk. - Diuretics (especially thiazides): may exacerbate electrolyte disturbances. - Anticoagulants (e.g., warfarin): desmopressin can enhance haemostatic activity, requiring clotting monitoring. - Antihistamines: may increase nasal mucosal dryness, affecting spray tolerance.